Drug Profile
Renal cell carcinoma vaccine - FBM Pharma
Alternative Names: Renal cell cancer vaccine - LipoNova; Renal cell cancer vaccine - Vaccentis; Reniale; VCC-001Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Liponova AG
- Developer FBM-PHARMA
- Class Cancer vaccines; Tumour cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Renal cell carcinoma
Most Recent Events
- 28 Jan 2019 Renal cell carcinoma vaccine is not yet available for Renal cell carcinoma (Adjuvant therapy) in Netherlands (Intradermal)
- 15 Jun 2015 Renal cell carcinoma vaccine is still in phase-III development in the EU
- 08 Feb 2014 Registered for Renal cell carcinoma (adjuvant therapy) in Austria (Intradermal) - First global approval